CA215 (0.1 Au/ml) | Cancer | Lung (n) | Liver (n) | Ovary (n) | Esophagus (n) | Breast (n) | Stomach (n) |
CEA (5 ng/ml) | Ia | 52% (112) | 74% (58) | - | 61% (23) | 71% (44) | 60% (30) |
IIb | 67% (33) | 54% (35) | 47% (19) | 95% (20) | 50% (14) | ||
IIIc | 94% | 81% | 65% | 96% | 70% | ||
AFP (20 ng/ml) | I | - | 74% (58) | - | - | - | - |
II | 50% (40) | ||||||
III | 85% | ||||||
CA125 (35 Au/ml) | I | 52% (112) | 74% (58) | 59% (68) | 61% (23) | - | - |
II | 85% (13) | 85% (13) | 59% (66) | 50% (12) | |||
III | 85% | 92% | 82% | 75% | |||
CA19-9 (37 Au/ml) | I | - | 74% (58) | - | - | - | 60% (30) |
II | 55% (22) | 75% (16) | |||||
III | 82% | 81% | |||||
CA15-3 (30 Au/ml) | I | - | - | - | - | 71% (44) | - |
II | 83% (6) | ||||||
III | 83% | ||||||
Β microglobulin (2.6 ng/ml) | I | - | 74% (58) | 59% (68) |
|
|
|
II | 56% (16) | 90% (10) | |||||
III | 81% | 100% | |||||
Cyfra21-1 (3.3 ng/ml) | I | 52% (112) | - | - | - | - | - |
II | 50% (52) | ||||||
III | 77% |